PL397595A1 - Przeciwnowotworowe bialko fuzyjne - Google Patents

Przeciwnowotworowe bialko fuzyjne

Info

Publication number
PL397595A1
PL397595A1 PL397595A PL39759511A PL397595A1 PL 397595 A1 PL397595 A1 PL 397595A1 PL 397595 A PL397595 A PL 397595A PL 39759511 A PL39759511 A PL 39759511A PL 397595 A1 PL397595 A1 PL 397595A1
Authority
PL
Poland
Prior art keywords
domain
fusion protein
sequence
tumor fusion
terminus
Prior art date
Application number
PL397595A
Other languages
English (en)
Other versions
PL223487B1 (pl
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Żerek
Piotr Kamil Rózga
Original Assignee
Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL397595A priority Critical patent/PL223487B1/pl
Priority to UAA201408554A priority patent/UA115436C2/uk
Priority to JP2014549601A priority patent/JP6324905B2/ja
Priority to KR1020147021158A priority patent/KR20140110017A/ko
Priority to MX2014008028A priority patent/MX352796B/es
Priority to SI201231178T priority patent/SI2797950T1/en
Priority to RS20180036A priority patent/RS56758B1/sr
Priority to PCT/IB2012/057657 priority patent/WO2013098755A2/en
Priority to NO12824731A priority patent/NO2797950T3/no
Priority to EP12824731.9A priority patent/EP2797950B1/en
Priority to LTEP12824731.9T priority patent/LT2797950T/lt
Priority to US14/367,681 priority patent/US20140377216A1/en
Priority to EA201491277A priority patent/EA201491277A1/ru
Priority to PT128247319T priority patent/PT2797950T/pt
Priority to SG11201403282QA priority patent/SG11201403282QA/en
Priority to PL12824731T priority patent/PL2797950T3/pl
Priority to BR112014015922-0A priority patent/BR112014015922A2/pt
Priority to NZ627445A priority patent/NZ627445B2/en
Priority to CA2859494A priority patent/CA2859494A1/en
Priority to ES12824731.9T priority patent/ES2655828T3/es
Priority to HUE12824731A priority patent/HUE035794T2/en
Priority to AU2012360086A priority patent/AU2012360086B2/en
Priority to CN201280060782.7A priority patent/CN103987728B/zh
Priority to DK12824731.9T priority patent/DK2797950T3/en
Publication of PL397595A1 publication Critical patent/PL397595A1/pl
Priority to IL232834A priority patent/IL232834A/en
Priority to PH12014501363A priority patent/PH12014501363A1/en
Priority to ZA2014/05460A priority patent/ZA201405460B/en
Priority to HK15102266.6A priority patent/HK1201848A1/xx
Publication of PL223487B1 publication Critical patent/PL223487B1/pl
Priority to HRP20180012TT priority patent/HRP20180012T1/hr
Priority to CY20181100048T priority patent/CY1120055T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04003—Phospholipase C (3.1.4.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bialko fuzyjne przeciwnowotworowe zawiera domene (a), która obejmuje funkcjonalny fragment sekwencji rozpuszczalnego bialka hTRAIL rozpoczynajacy sie aminokwasem w pozycji nie nizszej niz hTRAIL95, i przynajmniej jedna domene (b) stanowiaca sekwencje cytolitycznego peptydu efektorowego o dzialaniu formujacym pory w blonie komórkowej, przy czym sekwencja domeny (b) jest przylaczona od strony C-konca i/lub N-konca domeny (a).
PL397595A 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne PL223487B1 (pl)

Priority Applications (30)

Application Number Priority Date Filing Date Title
PL397595A PL223487B1 (pl) 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne
KR1020147021158A KR20140110017A (ko) 2011-12-28 2012-12-22 항암 융합 단백질
NZ627445A NZ627445B2 (en) 2011-12-28 2012-12-22 Anticancer fusion protein
PL12824731T PL2797950T3 (pl) 2011-12-28 2012-12-22 Przeciwnowotworowe białko fuzyjne
MX2014008028A MX352796B (es) 2011-12-28 2012-12-22 Proteina de fusion anticancerigena.
SI201231178T SI2797950T1 (en) 2011-12-28 2012-12-22 Fusion protein against cancer
RS20180036A RS56758B1 (sr) 2011-12-28 2012-12-22 Antikancer fuzioni protein
PCT/IB2012/057657 WO2013098755A2 (en) 2011-12-28 2012-12-22 Anticancer fusion protein
NO12824731A NO2797950T3 (pl) 2011-12-28 2012-12-22
EP12824731.9A EP2797950B1 (en) 2011-12-28 2012-12-22 Anticancer fusion protein
LTEP12824731.9T LT2797950T (lt) 2011-12-28 2012-12-22 Priešvėžinis sulietas baltymas
US14/367,681 US20140377216A1 (en) 2011-12-28 2012-12-22 Anticancer fusion protein
EA201491277A EA201491277A1 (ru) 2011-12-28 2012-12-22 Противораковый слитый белок
PT128247319T PT2797950T (pt) 2011-12-28 2012-12-22 Proteína de fusão anticancerígena
SG11201403282QA SG11201403282QA (en) 2011-12-28 2012-12-22 Anticancer fusion protein
UAA201408554A UA115436C2 (uk) 2011-12-28 2012-12-22 Протираковий злитий протеїн
BR112014015922-0A BR112014015922A2 (pt) 2011-12-28 2012-12-22 proteína de fusão anticâncer
DK12824731.9T DK2797950T3 (en) 2011-12-28 2012-12-22 Anticancer-fusionsprotein
CA2859494A CA2859494A1 (en) 2011-12-28 2012-12-22 Anticancer fusion protein
ES12824731.9T ES2655828T3 (es) 2011-12-28 2012-12-22 Proteína de fusión antineoplásica
HUE12824731A HUE035794T2 (en) 2011-12-28 2012-12-22 Cancer fusion protein
AU2012360086A AU2012360086B2 (en) 2011-12-28 2012-12-22 Anticancer fusion protein
CN201280060782.7A CN103987728B (zh) 2011-12-28 2012-12-22 抗癌融合蛋白
JP2014549601A JP6324905B2 (ja) 2011-12-28 2012-12-22 抗がん融合タンパク質
IL232834A IL232834A (en) 2011-12-28 2014-05-27 Antisertic union protein
PH12014501363A PH12014501363A1 (en) 2011-12-28 2014-06-16 Anticancer fusion protein
ZA2014/05460A ZA201405460B (en) 2011-12-28 2014-07-24 Anticancer fusion protein
HK15102266.6A HK1201848A1 (en) 2011-12-28 2015-03-05 Anticancer fusion protein
HRP20180012TT HRP20180012T1 (hr) 2011-12-28 2018-01-04 Antikancerogeni fuzijski protein
CY20181100048T CY1120055T1 (el) 2011-12-28 2018-01-16 Αντικαρκινικη πρωτεϊνη συντηξης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL397595A PL223487B1 (pl) 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne

Publications (2)

Publication Number Publication Date
PL397595A1 true PL397595A1 (pl) 2013-07-08
PL223487B1 PL223487B1 (pl) 2016-10-31

Family

ID=47716118

Family Applications (2)

Application Number Title Priority Date Filing Date
PL397595A PL223487B1 (pl) 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne
PL12824731T PL2797950T3 (pl) 2011-12-28 2012-12-22 Przeciwnowotworowe białko fuzyjne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12824731T PL2797950T3 (pl) 2011-12-28 2012-12-22 Przeciwnowotworowe białko fuzyjne

Country Status (28)

Country Link
US (1) US20140377216A1 (pl)
EP (1) EP2797950B1 (pl)
JP (1) JP6324905B2 (pl)
KR (1) KR20140110017A (pl)
CN (1) CN103987728B (pl)
AU (1) AU2012360086B2 (pl)
BR (1) BR112014015922A2 (pl)
CA (1) CA2859494A1 (pl)
CY (1) CY1120055T1 (pl)
DK (1) DK2797950T3 (pl)
EA (1) EA201491277A1 (pl)
ES (1) ES2655828T3 (pl)
HK (1) HK1201848A1 (pl)
HR (1) HRP20180012T1 (pl)
HU (1) HUE035794T2 (pl)
IL (1) IL232834A (pl)
LT (1) LT2797950T (pl)
MX (1) MX352796B (pl)
NO (1) NO2797950T3 (pl)
PH (1) PH12014501363A1 (pl)
PL (2) PL223487B1 (pl)
PT (1) PT2797950T (pl)
RS (1) RS56758B1 (pl)
SG (1) SG11201403282QA (pl)
SI (1) SI2797950T1 (pl)
UA (1) UA115436C2 (pl)
WO (1) WO2013098755A2 (pl)
ZA (1) ZA201405460B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
GB201406705D0 (en) 2014-04-15 2014-05-28 Univ Liverpool Fusion proteins,polynucleotides,expression vectors, and their uses
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN107216385A (zh) * 2017-05-19 2017-09-29 何向锋 肿瘤特异性重组水蛭素及其制备方法和用途
CN109400711B (zh) * 2017-05-31 2022-02-08 四川大学华西医院 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
WO2019067740A1 (en) * 2017-09-27 2019-04-04 Emory University FUSION PROTEINS COMPRISING CANCER TOXIN AND MARKER, NANOPARTICLES AND USES THEREOF
CN111909275A (zh) * 2019-05-08 2020-11-10 上海大学 延长多肽药物循环半衰期的靶向载药体系及其构建方法
CN110669146B (zh) * 2019-10-24 2023-05-23 常州大学 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN114031673B (zh) * 2021-12-22 2023-09-22 杭州长龄生物科技有限公司 一种多肽及其制备方法
CN114605517B (zh) * 2022-05-12 2022-09-27 广东海洋大学 一种具有广谱抗癌作用的多肽lxp-7及其应用
CN116063389B (zh) * 2022-08-23 2023-07-07 广州医科大学 递送核酸药物的多肽载体、治疗肿瘤的核酸药物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025616A1 (en) 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
KR101004174B1 (ko) 1995-06-29 2010-12-24 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
CA2544473C (en) 2003-11-03 2013-08-13 Beijing Sunbio Biotech Co., Ltd. A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
ATE540318T1 (de) 2005-08-16 2012-01-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CA2713126C (en) * 2008-01-24 2017-08-15 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer

Also Published As

Publication number Publication date
HRP20180012T1 (hr) 2018-02-09
HK1201848A1 (en) 2015-09-11
KR20140110017A (ko) 2014-09-16
PL223487B1 (pl) 2016-10-31
EP2797950A2 (en) 2014-11-05
WO2013098755A3 (en) 2013-08-29
IL232834A0 (en) 2014-07-31
LT2797950T (lt) 2018-02-12
CN103987728A (zh) 2014-08-13
SI2797950T1 (en) 2018-02-28
EA201491277A1 (ru) 2014-09-30
ZA201405460B (en) 2015-04-29
MX352796B (es) 2017-12-07
EP2797950B1 (en) 2017-10-18
JP2015504052A (ja) 2015-02-05
CY1120055T1 (el) 2018-12-12
AU2012360086A1 (en) 2014-08-07
NO2797950T3 (pl) 2018-03-17
PH12014501363A1 (en) 2014-09-22
HUE035794T2 (en) 2018-05-28
PL2797950T3 (pl) 2018-03-30
UA115436C2 (uk) 2017-11-10
US20140377216A1 (en) 2014-12-25
PT2797950T (pt) 2018-01-24
MX2014008028A (es) 2014-08-21
JP6324905B2 (ja) 2018-05-16
WO2013098755A2 (en) 2013-07-04
RS56758B1 (sr) 2018-04-30
DK2797950T3 (en) 2018-01-22
SG11201403282QA (en) 2014-07-30
BR112014015922A2 (pt) 2020-10-27
CA2859494A1 (en) 2013-07-04
CN103987728B (zh) 2017-05-10
NZ627445A (en) 2016-01-29
IL232834A (en) 2017-09-28
AU2012360086B2 (en) 2016-12-22
ES2655828T3 (es) 2018-02-21

Similar Documents

Publication Publication Date Title
PL397595A1 (pl) Przeciwnowotworowe bialko fuzyjne
CO2017004318A2 (es) Variantes de interferon α2b
PH12017501417A1 (en) Anti-fap antibodies and methods of use
MX2016008539A (es) Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas.
PH12014501083A1 (en) Anticancer fusion protein
EA201591731A1 (ru) АГЛИКОЗИЛИРОВАННЫЕ Fc-СОДЕРЖАЩИЕ ПОЛИПЕПТИДЫ
MX2017006866A (es) Pares de unión para producción de péptidos.
MX360741B (es) Constructos de polipéptidos y sus usos.
WO2014026054A3 (en) CD20 scFv-ELPs METHODS AND THERAPEUTICS
MX337436B (es) Proteina de funsion anticancer.
MX339203B (es) Proteina de fusion anticancer.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
EA201591609A1 (ru) Варианты альфа-амилазы
NZ724133A (en) Tfpi inhibitors and methods of use
WO2012143477A3 (en) Anticancer fusion protein
PH12015502072B1 (en) Nutritional compositions containing a peptide component and uses thereof
MY178931A (en) Polypeptides with permease activity
CA3080256A1 (en) Wnt5a peptides in reduction of cancer stem cells
LV15035A (lv) Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem
MY178192A (en) Recombinant protein